## DAFTAR PUSTAKA

Brufsky, A.M. dan Dickler, M. N. 2018. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. *The Oncologist* 23: 528–539.

Chabner B, *et al.*. 2014. *Harrison's manual of oncology 2nd Edition.* United States: MacGraw-Hill Education.

Chatamy, Fauziah Putri., Hasanah, Nurul., Irawiraman, Hadi. 2022. Usia dan Paritas Tidak Berhubungan dengsan Ekspresi Estrogen Reseptor (ER) dan Progesteron Reseptor (PR) pada Kanker Payudara Invasif No Special Type (NST) di RSUD Abdul Wahab Sjahranie Samarinda. *Jurnal Sains Kesehatan* 4: 126-131.

Crespo, James., Sun, Hongxia., Wu, Jimin., Ding, Qing-Qing., Tang, Guilin., Robinson, Melissa K., Chen, Hui., Sahin, Aysegul., Lim, Bora. 2020. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. *Journals Plos One*: 1 – 14.

Dahlan, M Sopiyudin. 2014. *Statistik Untuk Kedokteran dan Kesehatan Seri 1 Edisi 6*. Jakarta: Epidemiologi Indonesia.

Dall, G.V. dan Britt, K.L. 2017. Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. *Front Oncology* 7: 110.

Eric, Ivan., Eric, Anamarija Petek., Kristek, Jozo., Koprivcic, Ivan., Babic, Marko. 2018. Breast Cancer In Young Women: Pathologic and Immunohistochemical Features. *Acta clinica Croatica* 57: 497 – 502.

Fortner, Renee T., Sisti, Julia., Chai, Boyang., Collins, Laura C., Rosner, Benard., Harkinson, Susan E., Tamimi, Ruslia M., Eliassen, A. Heather. 2019. Parity, Breastfeeding, and Breast Cancer Risk by Hormon Receptor Status and Molecular Phenotype: Results from The Nusrses' Health Studies. *Breast Cancer Research* 21: 1 – 9.

Howlader, Nadia., Cronin, Kathleen A., Kurian, Allison A., Andridge, Rebecca. 2018. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiology Biomarkers Prev 27:619-626.

Jorns, J.M. 2019. Challenges in routine estrogen receptor, progesterone receptor, and HER2/neu evaluation. *Archives of Pathology and Laboratory Medicine* 143: 1444–1449.

Kementerian Kesehatan RI. 2015. *Panduan Nasional Penanganan Kanker Payudara*. Jakarta: Komite Nasional Penanggulangan Kanker.

Kudela, E., *et al*. 2019. Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach. *Cancers* 11: 1791.

Kumar, Pankaj dan Aggarwal, Rupali. 2016. An overview of triple-negative breast cancer. *Arch Gynceol Obstetri* 293: 247 – 269.

Kumar, Vinay., *et al*.. 2015. *Robbins and Cotran Pathologic Basis of Disease Ninth Edition*. Chicago: Illinois.

Lumachi, F. *et al.* 2013. Treatment of Estrogen Receptor-Positive Breast Cancer. *Current Medicinal Chemistry* 20: 596–604.

Mescher, A.L. 2019. *Junqueira's Basic Histology: Text & Atlas 15th edition.* Jakarta: EGC.

Pangribowo, S. 2019. Beban Kanker di Indonesia. *Pusat Data Dan Informasi Kesehatan Kementerian Kesehatan RI*: 1–16.

Pandit, *et al*.. 2020. Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. *Eur J Breast Health* 16: 39 – 43.

Prastyo Kurniati, Y. dan Nafiah, I. 2019. Fenotipe Estrogen Reseptor Berdasarkan Usia dan Pekerjaan Pada Kanker Payudara Invasif. *University Research Colloqium*: 709–715.

Provenzano, E., Ulaner, G.A. dan Chin, S.F. 2018. Molecular Classification of Breast Cancer. *PET Clinics* 13: 325–338.

Putri NM. 2018. *Hubungan antara usia dan body mass index (BMI) dengan fenotipe molekuler estrogen reseptor (ER) pada pasien invasive breast carcinoma of no special type (NST) di rumah sakit PKU Muhammadiyah Surakarta*. Surakarta: Universitas Muhammadiyah Surakarta.

Ritte, Rebecca., Lukanova, Annekatrin., Tjonneland, Anne., Olsen, Anja., Overvad, Kim., Mesrine, Sylvie., Fagherazzi, Guy., *et al*.. 2013. Height, age at menarche and risk of horsmone receptor-positive and -negative breast cancer: A cohort study. *International Journal of Cancer* 132: 2619 – 2629.

Sari, S.E., Harahap, W.A. dan Saputra, D. 2018. Pengaruh Faktor Risiko Terhadap Ekspresi Reseptor Estrogen Pada Penderita Kanker Payudara Di Kota Padang. *Jurnal Kesehatan Andalas* 7: 461.

Shah, R., Rosso, K. dan David Nathanson, S. 2014. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World Journal of Clinical Oncology* 5: 283–298.

Sidauruk, J.T.S. 2020. Hubungan Usia Dengan Estrogen Receptor Pada Penderita Kanker Payudara di RSUD Dr. Pirngadi Medan Tahun 2018. *Nommensen Journal of Medicine* 6: 1 – 4.

Smolarz, B., Zadrożna Nowak, A. dan Romanowicz, H. 2022. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment. Review of Literature. *Cancers* 14: 1–27.

Suparman, Erna and Suparman, Eddy. 2014. Peran Estrogen Dan Progesteron Terhadap Kanker Payudara. *Jurnal Biomedik (Jbm)* 6: 141–148.

Tortora, Gerald J. dan Derrickson, B.H.. 2013. *Principles of Anatomy and Physiology 14$^{th}$ Edition.* New York: John Wiley and Sons.

Tse, *et al*.. 2015. Familial Risks and Estrogen Receptor-Positive Breast Cancer in Hong Kong Chinese Women. Journal Plos one: 1 – 9.

Yip, C.H. and Rhodes, A. 2014. Estrogen and progesterone receptors in breast cancer. *Future Oncology* 10: 2293–2301.